A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.

Harrison SA, Bedossa P, Guy CD, et al. N Engl J Med. 2024;390(6):497-509.

Tirzepatide once weekly for the treatment of obesity.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216.

Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study.

Jensen AB, Renström F, Aczél S, et al. Obes Surg. 2023;33(4):1017-1025.

Resmetirom: an orally administered, small molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Karim G, Bansal MB. touchREV Endocrinol. 2023;19(1):60-70.

Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups.

Li M, Chen W, Deng Y, Xie W. Nutr Metab Cardiovasc Dis. 2024;34(9):2085-2094. 

Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. 

Loomba R, Abdelmalek MF, Armstrong MJ, et al. Lancet Gastroenterol Hepatol. 2023;8(6):511-522.

Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.

Loomba R, Hartman ML, Lawitz EJ, et al. N Engl J Med. 2024;391(4):299-310.

Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis.

Noureddin M, Charlton MR, Harrison SA, et al. Clin Gastroenterol Hepatol. 2024:S1542-3565(24)00667-0.

Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.

Noureddin N, Copur-Dahi N, Loomba R. Aliment Pharmacol Ther. 2024;59(suppl 1):S41-S51.

Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.

Pais R, Aron-Wisnewsky J, Bedossa P, et al. Hepatology. 2022;76(2):456-468.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Rinella ME, Lazarus JV, Ratziu V, et al. Hepatology. 2023;78(6):1966-1986. 

Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis.

Sanyal AJ, Newsome PN, Kliers I, et al. N Engl J Med. 2025. [Epub ahead of print] 

Once-weekly semaglutide in adults with overweight or obesity.

Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002.

Epidemiology of metabolic dysfunction-associated steatotic liver disease.

Younossi ZM, Kalligeros M, Henry L. Clin Mol Hepatol. 2025;31(Suppl):S32-S50.